Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes

US11390651B2 · kind B2 · utility

Assignees

• The USA, Secretary, DHHS · US
• CODAGENIX INC. · US

Inventors

• Cyril Lenouen · Bethesda, US
• Ursula Buchholz · Silver Spring, US
• Peter L. Collins · Kensington, US
• Steffen Mueller · Pforzheim, DE

Key dates

• Filing date: Aug 31, 2020
• Grant date: Jul 19, 2022
• Expiry date: Jan 16, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/00062
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.